Advanced Search
Ongoing Studies
Explore 1,105 in progress health studies in the Philippines

CATEGORY


SEARCH FILTER

Year
-




Region

Sponsor Classification



  
Results 1071 - 1080 of 1105

A Study to Investigate How Effective and Safe Solifenacin Liquid Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Implementing Agency
PPD Development (S) PTE. LTD.
Project Description
Solifenacin succinate as a tablet formulation is already on the market for the treatment of symptoms of overactive bladder in adults. For the use in children and adolescent patients a new formulation of solifenacin has been developed. This study will investigate the effect and safety of solifenacin . . .
Cooperating Sponsor
Astellas Pharma Europe B.V.
Date of Registration
19 November 2012
Region
NCR
Sources of Monetary or Material Support
Astellas Pharma Europe B.V.
Primary Outcomes
Change from baseline to EoT (final visit) in mean volume voided per micturition [ Time Frame: Baseline and Week 12 ] The mean voided volume will be determined using the patient diary data of two days (e.g., during the weekend).
Health Condition(s) or Problem(s) Studied
Overactive Bladder

Studies on Selected Medicinal Plants in Mindanao

Implementing Agency
Mindanao State University - Iligan Institute of Technology, College of Science and Mathematics
Project Description
This project is part of the first phase of a program which ultimately aims to produce herbal preparations or pure therapeutic drug leads sourced out from medicinal plants found in Mindanao. The first phase of this program is exploratory and holistic in nature in the sense t . . .
Date of Registration
08 November 2012
Region
Region X
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
cancer, infectious diseases including MRSA, TB and malaria

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis (MAGIC-2)

Implementing Agency
Astellas Pharma Global Development, Inc.
Project Description
The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
Cooperating Sponsor
PPD Development (S) PTE. LTD.
Date of Registration
05 August 2013
Region
United States of America
Sources of Monetary or Material Support
Astellas Pharma Global Development, Inc.
Primary Outcomes
Primary Outcome Measures: •Fungal free survival [ Time Frame: One week following the last dose of study drug (maximum of 49 days) ] [ Designated as safety issue: No ] Defined as alive at one week following the last dose of study drug and eradication (fungal free) with no requirement for alterna . . .
Health Condition(s) or Problem(s) Studied
Candidiasis

Prevalence of HIV Infection Among At Risk Populations at the Philippine General Hospital

Implementing Agency
National Institutes of Health - University of the Philippines - Manila, Institute of Molecular Biology and Biotechnology
Project Description
This study aims to determine the prevalence of HIV among at-risk populations at the Philippine General Hospital.
Cooperating Sponsor
University of the Philippines - Philippine General Hospital
Date of Registration
01 October 2013
Region
NCR
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Primary Outcomes
Prevalence measurement
Health Condition(s) or Problem(s) Studied
HIV

Using the e-Health Platform for Stakeholder Convergence and Public Advocacy in Support of the Drug Discovery and Development Program (DDDP)

Implementing Agency
Ateneo de Manila University, Institute of Philippine Culture
Project Description
This project aims to redevelop the PCHRD's eHealth Philippines platform and to utilize the platform to facilitate stakeholder convergence and public advocacy in support for the Drug Discovery and Development Program (DDDP ) of PCHRD towards broader research partnerships and collaboration. In achie . . .
Date of Registration
25 January 2013
Region
NCR
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
Health Information System; Medicinal Plant Research

Medicinal properties of purple yam and manunggal

Implementing Agency
Visayas State University
Project Description
PRP-1 (PhilRootcrops Protein-1) is a naturally-derived angiotensin-converting-enzyme (ACE) inhibitor from yam. Likewise, manunggal is a folkloric medicinal plant that is popularly used by herbal practitioners for treatment of chronic metabolic diseases. The number of people suffering from hypertensi . . .
Date of Registration
13 September 2013
Region
Region VIII
Sources of Monetary or Material Support
DOST Central Office
Primary Outcomes
data on the antidiabetic and antihypertensive properties of PRP-1 from purple yam and manunggal
Health Condition(s) or Problem(s) Studied
diabetes and hypertension

The Prevalence of Genetic Polymorphisms Associated with the Risk for the Development of Hypertension, Dyslipidemia, and Coronary Artery Disease among Filipinos

Implementing Agency
University of the Philippines, Philippine Genome Center
National Institutes of Health - University of the Philippines - Manila, Institute of Human Genetics
Project Description
The project aims to identify the prevalence of candidate genetic variations associated with hypertension, dyslipidemia and coronary artery disease among Filipinos.
Cooperating Sponsor
University of the Philippines - Philippine General Hospital, Department of Medicine, Section of Cardiology
Date of Registration
24 November 2015
Region
NCR
NCR
Sources of Monetary or Material Support
Philippine Council for Health Research and Development, Department of Science and Technology
Primary Outcomes
Determination of significant biomarkers in the form of genomic SNP markers that are predictive of various cardiovascular conditions.
Health Condition(s) or Problem(s) Studied
Cardiovascular Diseases
- hypertension
- coronary artery disease
- dyslipidemia
- stroke

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Implementing Agency
PPD Development (S) PTE. LTD.
National Institutes of Health - University of the Philippines - Manila, Institute of Human Genetics
Project Description
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung can . . .
Cooperating Sponsor
PPD Development (S) PTE. LTD.
Date of Registration
07 February 2013
Region
NCR
NCR
Sources of Monetary or Material Support
Genentech, Inc.
Primary Outcomes
Primary Outcome Measures: •Progression-free survival (tumor assessments according to RECIST criteria) [ Time Frame: up to approximately 23 months ] •Progression-free survival: Subgroup of patients with Met diagnostic positive tumors [ Time Frame: up to approximately 23 months ]
Health Condition(s) or Problem(s) Studied
Stage IIIB or IV non-squamous non-small cell lung cancer

Maternal and Child Health Care Services Delivery to Internally Displaced Persons

Implementing Agency
Mindanao State University - Maguindanao
National Institutes of Health - University of the Philippines - Manila, Institute of Human Genetics
Project Description
This research is about the survey of maternal and child health care services availed by Internally Displaced Persons (IDP) and Non-Internally Displaced Persons Non-IDP) in Eastern Maguindanao
Cooperating Sponsor
Mindanao State University - Marawi
Date of Registration
09 July 2013
Region
ARMM
NCR
Sources of Monetary or Material Support
Pfizer Inc.
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
Maternal and Child Health Care Delivery

MCH delivery to IDPs in ARMM

Implementing Agency
Mindanao State University - Marawi
Mindanao State University - Maguindanao
Project Description
The project is a cross-sectional descriptive study aimed to determine access and utilization of maternal and child health care services by IDP compared by non-IDP’s in the two provinces of ARMM namely: Lanao del Sur & Maguindanao
Cooperating Sponsor
Mindanao State University - Marawi
Date of Registration
15 July 2013
Region
ARMM
ARMM
Sources of Monetary or Material Support
Pfizer Inc.
Philippine Council for Health Research and Development, Department of Science and Technology
Health Condition(s) or Problem(s) Studied
Maternal and Child Health Care Services and Delivery to Internally Displaced Persons (IDPs) in ARMM

Loading…
©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date